

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A medical device comprising:
an implantable structure;
a basecoat matrix, including a combination of rapamycin and mycophenolic acid, in therapeutic dosages, incorporated in a first polymeric material, the basecoat matrix being affixed to the surface of the implantable medical device; and
a topcoat, including a second polymeric material, affixed to the basecoat matrix for controlling the elution rate of the rapamycin and mycophenolic acid, the first and second polymeric materials comprising immiscible polymers forming a chemical and physical barrier to the elution of the rapamycin and the mycophenolic acid, one of the immiscible polymers comprising a fluoropolymer and one of the immiscible polymers comprising an acrylic.
2. (Original) The medical device according to claim 1, wherein the implantable structure comprises a stent.
3. (Original) The medical device according to claim 1, wherein the implantable structure comprises a stent-graft.
4. (Original) The medical device according to claim 1, wherein the implantable structure comprises an anastomosis device.
5. (Cancelled) The medical device according to claim 1, wherein the second polymeric material is incompatible with the first polymeric

material, thereby creating both a physical and chemical barrier to the elution of the rapamycin and mycophenolic acid.

6. (Cancelled) The medical device according to claim 5, wherein the first polymeric material comprises a fluoropolymer.

7. (Cancelled) The medical device according to claim 5, wherein the second polymeric material comprises an acrylic.

8. (Cancelled) A method for treating restenosis comprising the local administration of therapeutic dosages of rapamycin and mycophenolic acid from a two-layered polymeric matrix including incompatible polymers.

9. (Currently Amended) A medical device comprising:
an implantable structure;
a basecoat matrix, including mycophenolic acid, in therapeutic dosages, incorporated in a first polymeric matrix, the basecoat matrix being affixed to the surface of the implantable medical device; and
a topcoat, including a second polymeric material and rapamycin, in therapeutic dosages, affixed to the basecoat matrix for controlling the elution rate of the rapamycin and the mycophenolic acid, the first and second polymeric materials comprising immiscible polymers forming a chemical and physical barrier to the elution of the rapamycin and the mycophenolic acid, one of the immiscible polymers comprising a fluoropolymer and one of the immiscible polymers comprising an acrylic.